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Entry into the critical pre-clinical ‘Good Laboratory Practice (GLP)’ stage of toxicology testing 
triggers significant R&D investment yet >20% of AstraZeneca’s potential new medicines 
have stopped for safety reasons in this GLP phase alone.  How could we avoid at least 
some of these costly failures?   An analysis of historical ‘stopping toxicities’ showed that > 
50% were attributable to target organ toxicities emerging within two weeks of repeat dosing 
or to acute cardiovascular risks.  By frontloading 2 week repeat dose toxicity studies and a 
comprehensive assessment of cardiovascular safety, we anticipate a potential 50% 
reduction in attrition in the GLP phase.  This will reduce animal use overall, save significant 
R&D costs and improve drug pipeline quality. 
 
 
Teaser: More than 20% of AstraZeneca’s potential new medicines were halted for 
safety reasons in the GLP testing phase alone – it is envisaged that a new approach 
could avoid at least some of these failures 
The overall decline in R&D productivity in pharmaceuticals over the past two decades is well 
documented [1, 2, 3, 4] In addition to the clear cost to patients in need of new therapies, the 
financial and reputational impact of late stage failures to the industry has also been 
significant. There are numerous factors underlying the productivity decline including a 
widespread industry focus on pipeline quantity rather than quality [5], heightened regulatory 
scrutiny[6] and an increasing focus of pharmaceutical company investment in areas of unmet 
medical need and unexploited biological mechanisms where there is a high risk of failure [2].  
Yet, for the pharmaceutical industry to be sustained in its present form, a dramatic increase 
in innovation and R&D productivity is required to replace the continued loss of revenues from 
patent expirations on successful products [3].  
 
Although a lack of clinical efficacy is the major cause of drug attrition, an unacceptable 
safety profile is also a major cause of development candidate failure [1, 7, 8], not only in the 
clinic, but at stages from drug candidate nomination through clinical development to post-
marketing surveillance. Building on this, some failures attributed to poor efficacy may 
actually arise because the toxicity profile prevents a sufficiently robust exploration of the 
efficacy dose response curve (dose-limiting toxicity). In facing this significant safety 
challenge, the pharmaceutical industry must improve its ability to predict the probability of 
subsequent failure due to toxicity earlier in the drug discovery process and become 
increasingly selective regarding the targets and compounds nominated for progression.  
 
Safety attrition is relatively common in the discovery (design) phase of drug development 
that takes place before candidate selection, where the identification of decision-driving 
chemical- or target-related toxicity is the primary aim of discovery toxicology strategies. At 
this early stage, there is an opportunity to ‘successfully’ halt programs prior to major 
investment or to influence chemical design away from the toxicity issue. However, these 
approaches, which often include in silico and in vitro methodologies, have not yet been 
consistently successful in predicting toxicities, particularly chemical- rather than target-driven 
ones, emerging upon repeat-dose in vivo exposure in the later regulatory Good Laboratory 
Practice (GLP) studies.  
 
Many potential new medicines are halted in the GLP Phase, before entry into humans. 
 
Before a new medicine can enter human clinical trials for the first time, safety and tolerability 
must be assessed in pre-clinical rodent and non-rodent studies both as a regulatory 
requirement and, more importantly, to assess, limit and manage risk to human volunteers or 
patients. The scientific rationale surrounding the use of animals in safety assessment studies 
to support human dosing has been reviewed elsewhere [9, 10]. Pre-clinical studies 
conducted prior to the initial phase 1 clinical investigations are required to characterise 
effects on function, target organ toxicity, to determine dose dependency and the relationship 
to drug exposure. Information from these studies is used to estimate initial safe starting 
doses and dose ranges, as well as to provide clinicians with key information to help develop 
suitable monitoring and patient exclusion strategies for these trials.   
 
The preclinical safety packages performed by pharmaceutical companies before 
commencing human Phase 1 clinical trials for small molecules are specified in regulatory 
guidance [11, 12] and, as such, the designs often have a high degree of similarity.  In 
general, toxicology studies of up to one month duration are suitable to support single or 
multiple dosing for a similar duration in Phase I clinical trials in human volunteers or patients 
[11].  Consequently, it is common practice within pharmaceutical companies to support initial 
Phase I studies in humans with toxicology studies of up to one month of duration in two 
species, conducted in accordance with GLP.   For most companies the decision to enter into 
this ‘GLP study phase’ is a critical milestone since it carries with it significant financial and 
resource investment across R&D.  However, a recent internal data analysis has shown that 
between 2001 and 2010 >20% of AstraZeneca’s potential new medicines were halted for 
safety reasons in the phase between the commencement of GLP toxicology studies and 
entry into humans. How could these toxicities be predicted, allowing us to avoid at least 
some of the failures in the future? 
 
Root causes of the attrition 
 
 An analysis of 48 candidate drugs (CDs) that were halted for adverse safety findings in the 
first GLP dose to FTIM window between 2001 and 2010 was conducted (in-house data – 
unpublished).  These 48 compounds represented 24% of the 198 AstraZeneca drug 
candidates nominated for development during this period. The primary cause of failure or 
‘stopping toxicity’ for each candidate was identified and the duration of dosing after which the 
toxicity was reported to emerge was then determined.   
Interestingly, at least 40% (Table 1) of the historical failures were attributable to target organ 
toxicities (detected by histopathology), or to unexplained deaths, that emerged within two 
weeks of repeat dosing.  For 8% of the failed candidates, it was clear that the toxicity was 
not or would not be detected by the end of two weeks dosing. For a further 11%, it was 
unclear if two weeks dosing would be sufficient for toxicity detection. This was most 
frequently because the toxicity had not been detected in a 1 week dose range finding(DRF) 
study but had been detected after a later 1 month study, yet no interim timepoint data were 
available.  In addition there were a number of candidate drugs (10%) that were halted due to 
acute cardiovascular risks that emerged in GLP dog telemetry studies, designed to detect 
alterations in cardiovascular parameters such as heart rate and blood pressure.  For the 
remaining 19% of projects, the decision to stop development in the GLP phase was based 
on other issues such as genetic toxicology, reactive metabolites or due to clinical safety 
signals in more advanced but closely related projects (Figure 1).  Regarding the candidate 
drugs halted due to genetic toxicology and cardiovascular risk during the GLP phase, current 
best practice in in silico and in vitro screening both for cardiovascular liability and for genetic 
toxicology is routinely employed at AstraZeneca and many potential candidate drugs 
carrying these liabilities are screened out along the route [13, 14, 15].  These assays 
typically increase in their sensitivity during the progression in time, complexity and cost from 
in silico to in vitro, to small scale non-GLP and finally to larger scale GLP screening.  On top 
of this increase in sensitivity, the hazard may have been detected in vitro but then falling 
margins once data is available in vivo could make progression less viable.  Thus, failures in 
the GLP phase are reduced but not removed by the earlier screening cascades.  Regarding 
the repeat dose toxicities that were detected at less than 2 weeks of dosing, these were 
distributed among a variety of target organs such as liver, lung, muscle, pancreas, 
cardiovascular system and thyroid gland (Table1).  
 
 
For most programs the only repeat dose in vivo data available for decision making at the 
time of compound nomination into development was from the maximum tolerated dose/dose 
range finding (MTD/DRF) studies conducted to set doses for the subsequent definitive GLP 
studies using only small numbers of animals (Figure 2a). Previously in AstraZeneca these 
non-GLP MTD/DRF studies traditionally followed a standard design where single rising 
doses are given to establish an MTD; once this is established a dose is selected for a short 
repeat dose phase routinely with 7 days of repeat dosing in the dose-range finding phase 
(Figure 2a).  For scientific and welfare reasons, common practice in AstraZeneca is to 
explore adverse effects in rodent species prior to non-rodent species. This increases the 
amount of information available for the design of the non-rodent studies; for example, 
data from the initial rodent study can be used to help set the starting dose, or to allow for 
specific monitoring of adverse effects in non-rodents. The non-rodent maximum tolerated 
dose/dose-range finding study design was based on an industry consensus paper [16].  The 
primary objective of the study was to establish the limit of tolerance to set the high dose for 
regulatory studies using one group of animals.  This design was used in AstraZeneca and 
was an optimal design alongside the pipeline quantity approach using the minimum number 
of non-rodents to rapidly move to the GLP studies. It is therefore not surprising that the 
‘stopping toxicities’ observed at 2 weeks were previously undetected at the decision to enter 
the GLP study phase.   
 Regarding the acute cardiovascular risks, these would not normally emerge until the non-
rodent telemetry study usually conducted in the GLP phase to support the risk assessment 
before entering into humans [17].  An exception to this would be if early, small animal 
cardiovascular studies have been performed perhaps driven by knowledge of a hightened, 
specific risk in this area.   
 
What is the significance for human risk assessment? 
 
A detailed analysis conducted by Olson et al examining the concordance of toxicities 
between animals and humans for 150 drugs demonstrated that while many adverse effects 
in humans were predicted by single-dose data, a significant proportion of human toxicities 
were only detected upon repeat dosing. The number of toxicities detected increased in line 
with dosing period, between one day and one month, with very few additional toxicities 
identified in longer experiments [18] 
 
Further to this Rozman and Doull emphasised the quantitative relationship between dose, 
time and toxicological outcome, particularly at the low end of the dose-response curve [19]. 
Increasing the dosing duration can reveal toxicity at lower exposure levels relative to short-
term studies, so it is important to explore the full toxicological dose-response curve to allow 
better contextualisation of any toxicity findings with respect to the predicted therapeutic 
exposure. 
 
What have we put in place? 
 
Based on the analysis, we have implemented a new pre-GLP approach with two key 
components (Figure 2b): 1) an extended repeat dose study (with a minimum of 14 days 
repeat dosing) to allow a more rigorous analysis of the probability of subsequent ‘stopping’ 
toxicities and their dose dependency and 2) a comprehensive assessment of cardiovascular 
safety in non-rodent models (previously conducted in the GLP phase). Regarding the 
extended repeat dose study, we have introduced 3 dose groups plus control in both the 
rodent and non-rodent study so that a dose response is established to give an early 
indication of margins to intended clinical exposure.  A full clinical pathology and pathology 
examination (see Table 2a and b) will be conducted on these studies to maximize the 
information available for decision making.  Echo cardiography and ophthalmoscopy are not 
routinely carried out on these studies unless a specific risk to be mitigated has been 
identified. Regarding animal numbers, the rodent study will use 3 animals per sex per group.  
The non-rodent study will be based on just one animal per sex per group rising to 2 if 
scientific justification indicates the need.  Clearly, these studies are designed to detect 
obvious safety signals early while minimizing animal usage and the numbers/group used 
have proven adequate for the purpose and are in line with industry practice [20].  Another 
key aspect of this approach is to ensure that the repeat dose study will also meet the 
requirements of setting doses for the GLP toxicology studies that should follow on rapidly for 
successful projects.    
 
In addition to this extended in vivo rodent and non-rodent MTD/DRF study, we have brought 
forward the non-rodent telemetry to give a comprehensive assessment of cardiovascular 
safety before commitment to GLP toxicology and all the investment that this step triggers. 
 
What do we hope to achieve? 
 
Overall, the new strategy should detect compounds that induce target organ toxicity within 
two weeks and also identify compounds with acute cardiovascular risks.  This retrospective 
analysis suggests that the strategy should bring drug candidate safety attrition forward, 
delivering the opportunity for up to a 50% reduction in attrition in the GLP phase (Figure 1).  
This makes some assumptions, primarily that our future candidate drugs will have a similar 
breadth of associated toxicological issues to those observed historically; this is not an 
unreasonable assumption since future drug candidates are likely to be derived from similar 
chemical space.  When modeled hypothetically with 100 drug projects entering discovery, a 
50% reduction in attrition in the GLP Phase (from 24% to 12%) (table 3) results in an 
improvement from 4 to 5 successful drug registrations, all other parameters on success at 
each stage of the pipeline being equal (Figure 3). 
 
Undoubtedly, the significant effort that has been invested in early in silico and in vitro 
methodologies has yielded results in enhancing compound selection to reduce attrition but 
has not yet been consistently successful in predicting toxicities, particularly chemical- rather 
than target-driven ones, emerging upon repeat-dose in vivo exposure in the later regulatory 
Good Laboratory Practice (GLP) studies. The new approach means a greater investment 
earlier in the development programme since more animals are now used in the MTD/DRF 
studies and the non-rodent telemetry study is conducted earlier. This in turn requires more 
compound to be synthesized at an earlier stage to enable more robust decision making.  
Additionally, the new approach will take slightly longer during this MTD/DRF phase but this 
can be offset in efficiencies of time during the GLP phase and should have minimal impact 
on time taken to get new candidate drugs to the clinic.  However,  if successful, this new 
approach will save significant R&D costs, increase efficiency by avoiding progressing 
unsuitable compounds thus reducing animal use overall for those individual programmes 
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Figure 1. 50% (green) of the compounds that failed in the phase between entry into GLP 
toxicology testing and entry into humans would have evoked ‘stopping toxicity’ in either 
extended 14-day DRF studies or the non-rodent telemetry studies normally conducted later 
in the development of a drug.  For an additional 23%(yellow) of projects it is unclear if these 
measures would allow detection after 2 wks repeat dosing as the toxicity was originally only 
assessed after 1 month.  The new strategy would certainly not have detected the toxicities 
for 8% (red) of projects as the toxicity was confirmed not to be present after 2 weeks repeat 
dosing.  The remaining 19% (grey) were stopped for reasons other than non-clinical in vivo 
toxicity such as clinical toxicity of CD1 informing a stop for CD2 in the pre-clinical phase.   
 
Figure 2.  Panel A depicts the model used for most drug programs, where dose range 
finding studies in rodents and non-rodents are conducted prior to the candidate selection 
investment decision (CSID) to set doses for the subsequent definitive GLP studies using 
only small numbers of animals.  Some programs may have early, small animal 
cardiovascular studies as an assessment of acute cardiovascular risks.  In the new model 
(Panel B), multi-purpose MTD/14 day repeat dose toxicity studies will be conducted in 
rodents and non-rodents at 3 doses plus control in support of the CSID decision.  The rodent 
study will use 3 per group both males and females whereas the non-rodent will be based on 
just one animal per group rising to 2 if compound amounts allow.  Non-rodent telemetry will 
also be moved prior to CSID to provide an assessment of acute cardiovascular risk.   
 
 
Figure 3.  Modeling the impact of a 50% reduction in attrition in the GLP Phase on 
subsequent drug project success.  Darker bars show 100 drug projects entering the lead 
generation phase of discovery transitioning through 7 key stages each with its own 
probability of success (POS).  Lighter bars show the impact on portfolio size of a reduction in 
attrition in the GLP phase from 24% to 12%, all other parameters being equal.  Note 
logarithmic axis starts at 1. 
 
 
